{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:24:20Z","timestamp":1775611460283,"version":"3.50.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Detection of circulating myeloma cells (CMCs) by flow cytometry in patients with multiple myeloma (MM) indicates active disease. We hypothesized that detection of CMCs at the time of stem-cell collection prior to autologous stem-cell transplantation (ASCT) identifies patients at high risk of rapid progression. A cohort of patients undergoing ASCT was identified. CMCs were determined by gating on CD38+\/CD45- cells using flow cytometry. The impact of CMCs on overall survival (OS) and time to progression (TTP) was evaluated in univariate and multivariate analyses. Of 246 patients undergoing ASCT, 95 had CMCs. Complete response (CR) rates after transplantation were 32% and 36% for patients with and without CMCs, respectively (P = .50). OSs were 33.2 and 58.6 months (P = .01) whereas TTPs were 14.1 and 22 months, respectively (P = .001). On multivariate analysis, CMCs remained independent of cytogenetics and disease status at time of transplantation (P = .03). CMCs and cytogenetics were combined in a new scoring system. Patients with neither, one, or both parameters had a median OS of 55, 48, and 21.5 months and a median TTP of 22, 15.4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management.<\/jats:p>","DOI":"10.1182\/blood-2005-08-3398","type":"journal-article","created":{"date-parts":[[2005,12,9]],"date-time":"2005-12-09T01:52:45Z","timestamp":1134093165000},"page":"3384-3388","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":69,"title":["Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system"],"prefix":"10.1182","volume":"107","author":[{"given":"David","family":"Dingli","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis A.","family":"Gastineau","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111711471498200_REF1","doi-asserted-by":"crossref","unstructured":"Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336: 1657-1664.","DOI":"10.1056\/NEJM199706053362307"},{"key":"2019111711471498200_REF2","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351: 1860-1873.","DOI":"10.1056\/NEJMra041875"},{"key":"2019111711471498200_REF3","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335: 91-97.","DOI":"10.1056\/NEJM199607113350204"},{"key":"2019111711471498200_REF4","doi-asserted-by":"crossref","unstructured":"Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89: 789-793.","DOI":"10.1182\/blood.V89.3.789"},{"key":"2019111711471498200_REF5","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349: 2495-2502.","DOI":"10.1056\/NEJMoa032290"},{"key":"2019111711471498200_REF6","doi-asserted-by":"crossref","unstructured":"Gertz MA, Lacy MQ, Inwards DJ, et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant. 2000;26: 45-50.","DOI":"10.1038\/sj.bmt.1702445"},{"key":"2019111711471498200_REF7","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Fonseca R, Lacy MQ, et al. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999;23: 1261-1266.","DOI":"10.1038\/sj.bmt.1701787"},{"key":"2019111711471498200_REF8","doi-asserted-by":"crossref","unstructured":"Rajkumar S, Fonseca R, Lacy M, et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999;24: 497-503.","DOI":"10.1038\/sj.bmt.1701943"},{"key":"2019111711471498200_REF9","doi-asserted-by":"crossref","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;p32), t(4;14)(p16.3; q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106: 2837-2840.","DOI":"10.1182\/blood-2005-04-1411"},{"key":"2019111711471498200_REF10","doi-asserted-by":"crossref","unstructured":"Witzig TE, Dhodapkar MV, Kyle RA, Greipp PR. Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer. 1993;72: 108-113.","DOI":"10.1002\/1097-0142(19930701)72:1<108::AID-CNCR2820720121>3.0.CO;2-T"},{"key":"2019111711471498200_REF11","doi-asserted-by":"crossref","unstructured":"Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant. 1997;19: 337-342.","DOI":"10.1038\/sj.bmt.1700670"},{"key":"2019111711471498200_REF12","doi-asserted-by":"crossref","unstructured":"Witzig TE, Kimlinger TK, Ahmann GJ, Katzmann JA, Greipp PR. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry. 1996;26: 113-120.","DOI":"10.1002\/(SICI)1097-0320(19960615)26:2<113::AID-CYTO3>3.0.CO;2-H"},{"key":"2019111711471498200_REF13","doi-asserted-by":"crossref","unstructured":"Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood. 1996;88: 1780-1787.","DOI":"10.1182\/blood.V88.5.1780.1780"},{"key":"2019111711471498200_REF14","doi-asserted-by":"crossref","unstructured":"Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106: 2276-2279.","DOI":"10.1182\/blood-2005-05-1858"},{"key":"2019111711471498200_REF15","doi-asserted-by":"crossref","unstructured":"Witzig TE, Meyers C, Therneau T, Greipp PR. A prospective study of CD38\/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders. Leuk Lymphoma. 2000;38: 345-350.","DOI":"10.3109\/10428190009087025"},{"key":"2019111711471498200_REF16","unstructured":"Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102: 1115-1123."},{"key":"2019111711471498200_REF17","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: 457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2019111711471498200_REF18","doi-asserted-by":"crossref","unstructured":"Cox D. Regression models with life tables (with discussion). J Roy Stat Soc. 1972;34: 187-220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2019111711471498200_REF19","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97: 46-55.","DOI":"10.1046\/j.1365-2141.1997.72653.x"},{"key":"2019111711471498200_REF20","doi-asserted-by":"crossref","unstructured":"Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92: 3131-3136.","DOI":"10.1182\/blood.V92.9.3131"},{"key":"2019111711471498200_REF21","doi-asserted-by":"crossref","unstructured":"Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348: 1875-1883.","DOI":"10.1056\/NEJMoa022340"},{"key":"2019111711471498200_REF22","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Fonseca R, Dispenzieri A, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant. 2000;26: 979-983.","DOI":"10.1038\/sj.bmt.1702640"},{"key":"2019111711471498200_REF23","doi-asserted-by":"crossref","unstructured":"Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19: 3771-3779.","DOI":"10.1200\/JCO.2001.19.17.3771"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/8\/3384\/1282447\/zh800806003384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/8\/3384\/1282447\/zh800806003384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T10:51:17Z","timestamp":1736160677000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/8\/3384\/22237\/Flow-cytometric-detection-of-circulating-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,15]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-08-3398","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,15]]}}}